Tetrabamate

Tetrabamate (Atrium, G Tril, Sevrium) is a combination drug formulation of febarbamate, difebarbamate, and phenobarbital which was marketed in France and Spain and was used to treat anxiety and alcohol withdrawal-associated muscle tremors, agitation, and depression.^[1][2][3][4] It was largely, but not completely discontinued on April 4, 1997, after over 30 years of use due to reports of hepatitis and acute liver failure.^[3][4][5][6] The decision to restrict the use of the drug had been long-awaited.^{[clarification needed][6]}